This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
HCPLive
AUGUST 31, 2024
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
Medical Xpress - Cardiology
DECEMBER 12, 2023
Stem cell-based therapy improved quality of life for patients with advanced heart failure, Mayo Clinic researchers and international collaborators discovered in a late-stage multinational clinical trial.
Cardiology Update
AUGUST 4, 2024
Despite proven benefits in reducing morbidity and mortality, many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). ESC Heart Failure 2024; 11 : 560–569. The post Digital Consults to Enhance Heart Failure Treatment: The ADMINISTER Trial appeared first on Cardiology Update.
119 
DAIC
JULY 25, 2024
BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.
111 
Becker's Hospital Review - Cardiology
JULY 9, 2024
New study finds strict sodium restrictions may not benefit heart failure patients. per day can improve quality of life Moderate salt intake of 3.0-4.5g
American College of Cardiology
AUGUST 2, 2024
Iron deficiency (ID) is a common comorbidity among patients with heart failure (HF), and it is associated with reduced exercise tolerance and quality of life and serves as a marker of increased risk of hospitalizations and mortality.
HCPLive
MARCH 14, 2024
The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.
HCPLive
AUGUST 27, 2024
Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.
52 
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
111 
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF.
DAIC
MAY 28, 2024
milla1cf Tue, 05/28/2024 - 07:00 May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heart failure, according to research presented at Heart Failure 2024 , a scientific congress of the European Society of Cardiology (ESC).
Science Daily - Heart Disease
AUGUST 30, 2024
In the ABYSS trial, the cardiovascular safety of interrupting beta-blocker could not be shown in comparison with beta-blocker continuation and beta-blocker interruption did not improve quality of life.
117 
European Journal of Heart Failure
DECEMBER 22, 2023
Abstract Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. This article is protected by copyright. All rights reserved.
European Journal of Heart Failure
NOVEMBER 29, 2023
ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Frontiers in Cardiovascular Medicine
JANUARY 28, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.
European Journal of Heart Failure
DECEMBER 13, 2023
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. The primary outcome was a composite of cardiovascular death or worsening heart failure. 0.93]; COPD: HR 0.82 [95% CI 0.62–1.10];
Circulation
NOVEMBER 11, 2023
Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 2.7,13.4), 4.6 (-0.6,9.9) for all).
Frontiers in Cardiovascular Medicine
FEBRUARY 13, 2024
Heart failure (HF) is recognized as an epidemic in the contemporary world, impacting around 1%–2% of the adult population and affecting around 6 million Americans. HF remains a major cause of mortality, morbidity, and poor quality of life.
Circulation: Heart Failure
OCTOBER 23, 2023
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010802, November 1, 2023. Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations.
Heart BMJ
FEBRUARY 12, 2024
Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heart failure (HF). Introduction Management of heart failure (HF) requires multidisciplinary, pharmacological and non-pharmacological strategies, one component of which is exercise training.
40 
Frontiers in Cardiovascular Medicine
APRIL 23, 2024
Refractory heart failure (RHF), or end-stage heart failure, has a poor prognosis and high case fatality rate, making it one of the therapeutic difficulties in the cardiovascular field.
Journal of Cardiovascular Electrophysiology
JANUARY 30, 2024
Abstract Introduction In hypertrophic cardiomyopathy (HCM), atrial fibrillation (AF) has historically been regarded to have a deleterious impact on clinical course, strongly associated with progressive heart failure (HF) symptoms. Therefore, we evaluated the impact of AF on QoL utilizing patient reported outcome measures (PROMs).
European Journal of Heart Failure
JANUARY 31, 2024
TAVR in heart failure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.
40 
The British Journal of Cardiology
AUGUST 21, 2024
Digoxin has been used in the management of chronic heart failure (HF) and atrial fibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.
Open Heart
JUNE 9, 2022
Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.
The American Journal of Cardiology
DECEMBER 30, 2023
Publication date: Available online 29 December 2023 Source: The American Journal of Cardiology Author(s): Lorenzo Braghieri, Arwa Younis, Chadi Tabaja, Pasquale Santangeli, Tyler Taigen, Walid I. Saliba, Oussama M. Wazni, Ayman A.
Circulation: Heart Failure
MARCH 5, 2024
Circulation: Heart Failure, Ahead of Print. with no difference between the treatment groups.
HeartRhythm
APRIL 30, 2024
Guidelines recommend permanent pacemaker (PPM) implantation in patients with sinus node dysfunction (SND) to improve quality of life. Patients with heart failure with preserved ejection fraction (HFpEF) have many comorbidities including SND, but the optimal treatment approach for HFpEF with SND is uncertain.
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2024
Background Exercise training is commonly employed as a efficacious supplementary treatment for individuals suffering from heart failure, but the optimal exercise regimen is still controversial. 41.70), and Minnesota Living with Heart Failure Questionnaire (MD = −4.45, 95% CI for −6.25 to −2.64) compared to MICT.
European Journal of Heart Failure
MARCH 11, 2024
This study found that treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure and reduced ejection fractions (HFrEF) was associated with lower skeletal muscle pathology. Muscle biopsies were collected from patients treated with SGLT2 inhibitors (>12 months) and compared to untreated controls.
HeartRhythm
APRIL 30, 2024
Catheter ablation (CA) for atrial fibrillation (AF) and heart failure with reduced ejection fraction <40% (HFrEF) is associated with improved outcomes. The patient characteristics, AF effect on quality-of-life questionnaire (AFEQT), and ablation strategies performed remains uncertain in those with and without HFrEF.
Circulation
SEPTEMBER 2, 2024
Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.
DAIC
APRIL 9, 2024
Decline in exercise ability is a hallmark of progression to overt heart failure. These results also speak to the importance of continuing to focus on earlier recognition of heart failure risk in patients with diabetes and on initiating treatment before the condition has progressed to overt heart failure.”
Open Heart
FEBRUARY 17, 2024
Objective To evaluate stress, depression and quality of life among community-dwelling patients with heart failure (HF) and evaluate their effect on perceived medication adherence in a socioeconomically challenged setting. were on ACE inhibitors/angiotensin receptor blockers and 54.9% on beta-blockers.
Open Heart
AUGUST 10, 2023
Background Atrial fibrillation (AF) is common in individuals with heart failure (HF). Individuals with HF and AF may have a reduced functional capacity and quality of life (QoL) which leads to hospital admission and burden on clinical services. Evidence supported the effect of exercise training in individuals with HF.
European Journal of Heart Failure
MARCH 4, 2024
Abstract Aims To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study.
Circulation
APRIL 3, 2024
Guideline-directed medical therapies and guideline-directed nonpharmacological therapies improve quality of life and survival in patients with heart failure (HF), but eligible patients, particularly women and individuals from underrepresented racial and ethnic groups, are often not treated with these therapies.
DAIC
APRIL 22, 2024
RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF). For more information: www.corviamedical.com If you enjoy this content, please share it with a colleague
European Journal of Heart Failure
SEPTEMBER 26, 2023
Exercise training in patients with advanced heart failure and left ventricular assist device (Ex-VAD) trial. Aims Small studies and observations suggested that exercise training may improve peak oxygen consumption (peakVO 2 ) in patients with advanced heart failure and left ventricular assist device (LVAD).
40 
European Journal of Heart Failure
OCTOBER 31, 2023
This 2023 Cochrane review of 60 randomized trials in 8728 heart failure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life.
Dr. Sanjay Gupta
MAY 23, 2022
Today’s vlog is on the subject of heart failure and in particular on a special type of pacemaker which can make a significant improvement to the quality of life and length of life in patients with heart failure. What is heart failure?
Open Heart
MAY 8, 2024
Background Despite maximal treatment, heart failure (HF) remains a major clinical challenge. In addition, trimetazidine improved (New York Heart Association) functional class (mean difference: –0.44 (95% CI –0.49 Besides neurohormonal overactivation, myocardial energy homoeostasis is also impaired in HF.
Journal of the American Heart Association
DECEMBER 29, 2023
BackgroundHeart failure with preserved ejection fraction ≥50% is prevalent with few evidence‐based therapies. These changes were paralleled by improvements in heart failure‐related quality of life (myPACE Minnesota Living with Heart Failure Questionnaire improved by 16.1 points,P<0.001).
Dr. Sanjay Gupta
MARCH 6, 2022
Today’s video is on the subject of heart failure. Heart failure is a chronic clinical syndrome characterised by the inability of the heart to pump out enough blood to meet the body’s requirements. Anything that affects the heart in a bad way may in its severest form lead to heart failure.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content